Top

Nifedipine (Adalat) discontinued from Australian Market

23 October 2019

Updated 23 September 2020

The Australian suppliers of immediate release nifedipine have discontinued 10mg and 20mg tablets from the Australian market. It is suggested that RANZCOG members contact the Director of Pharmacy at the hospital they attend for information regarding availability and quality of immediate release nifedipine.

An alternative option is to procure the product from overseas through the Special Access Scheme (SAS) via the TGA. However, at present the TGA are unsure what other countries are producing the immediate release formulation.  In addition, the use of nifedipine for tocolysis is off-label. For this reason, the TGA are unable to endorse supply. 

The SAS allows medical practitioners to become authorized prescribers who are then approved to prescribe unapproved therapeutic goods for a particular condition or class of patients in their immediate care without further TGA approval. Additional information regarding the SAS and becoming an authorized prescriber can be found at https://www.tga.gov.au/form/authorised-prescribers

Further information can be found on the TGA website https://apps.tga.gov.au/Prod/msi/Search/Details/nifedipine 
 



MEDIA CENTRE

Women's Health

New recommendation for College statement Instrumental vaginal birth (C-Obs 16)

In light of new findings from the ANODE trial, a new recommendation was included in the College statement Instrumental vaginal birth (C-Obs 16).

21/04/2020

Women's Health

Nifedipine (Adalat) discontinued from Australian Market

The Australian suppliers of immediate release nifedipine have discontinued 10mg and 20mg tablets from the Australian market.
 

23/10/2019

Women's Health

Management of shoulder dystocia by post axillary sling traction

A communiqué has been published outlining RANZCOG's stance on the management of shoulder dystocia by post axillary sling traction.

10/04/2019